Binnopharm Group presented a drug for women’s health

Binnopharm Group, a leading player in the Russian pharmaceutical market, is announcing its major entry into the women’s health sector with a new line of gynaecological drugs. The first drug in the series, which is intended for the treatment of endometriosis, is already available in pharmacies. Within the first week of entering the market, over 30,000 packages were shipped to distributors. The other four drugs are either in the final stage of registration or have already received marketing authorisation.

This line has been designed to address the key needs of women of all ages, from adolescence to menopause. All the drugs have a proven efficacy and a high safety profile.

Ekaterina Slavgorodskaya, Sales and Promotion Director at Binnopharm Group: «In 2025, the Binnopharm Group’s gynaecological product line consists of five specially developed drugs designed to address key women’s health needs. The first product for endometriosis therapy is now available from pharmacies and online retailers, and the first prescriptions have been issued. In the near future, we will gradually introduce the remaining four drugs to the market. In 2026, we plan to launch two more new products, with further expansion of our product range. We believe that it is important for every woman in Russia to have access to modern and safe healthcare solutions».

To promote the product line, the company is focusing on collaborating with leading medical associations and gynaecology experts. Working actively with electronic marketplaces and pharmacy chains will ensure the wide availability of medicines. Educational initiatives for doctors and patients will raise awareness of modern therapies and contribute to the well-being of women everywhere.

By the end of 2030, the Binnopharm Group’s sales of gynaecological drugs are expected to exceed 18 billion roubles. However, the medical community and Russian women’s trust will be the key indicators of success, rather than financial results.